Biomarin Pharmaceutical Inc Financials

BMRN

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Financial Profile 80/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Biomarin Pharmaceutical Inc has an operating margin of 17.0%, meaning the company retains $17 of operating profit per $100 of revenue. This strong profitability earns a score of 85/100, reflecting efficient cost management and pricing power. This is up from 7.7% the prior year.

Growth

Biomarin Pharmaceutical Inc's revenue surged 18.0% year-over-year to $2.9B, reflecting rapid business expansion. This strong growth earns a score of 80/100.

Leverage

100

Biomarin Pharmaceutical Inc carries a low D/E ratio of 0.24, meaning only $0.24 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 5.33, Biomarin Pharmaceutical Inc holds $5.33 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

Biomarin Pharmaceutical Inc converts 17.1% of revenue into free cash flow ($487.4M). This strong cash generation earns a score of 85/100.

Returns

Biomarin Pharmaceutical Inc's ROE of 7.5% shows moderate profitability relative to equity, earning a score of 30/100. This is up from 3.4% the prior year.

Altman Z-Score Safe

6.23

Biomarin Pharmaceutical Inc scores 6.23, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($11.5B) relative to total liabilities ($1.3B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Strong

7/9

Biomarin Pharmaceutical Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.34x

For every $1 of reported earnings, Biomarin Pharmaceutical Inc generates $1.34 in operating cash flow ($572.8M OCF vs $426.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

38.2x

Biomarin Pharmaceutical Inc earns $38.2 in operating income for every $1 of interest expense ($484.2M vs $12.7M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

This page shows Biomarin Pharmaceutical Inc (BMRN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

$2.9B

YoY+18.0%

5Y CAGR+10.9%

10Y CAGR+14.3%

Biomarin Pharmaceutical Inc generated $2.9B in revenue in fiscal year 2024. This represents an increase of 18.0% from the prior year.

EBITDA

$580.6M

YoY+100.1%

5Y CAGR+160.5%

Biomarin Pharmaceutical Inc's EBITDA was $580.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.1% from the prior year.

Free Cash Flow

$487.4M

YoY+679.0%

Biomarin Pharmaceutical Inc generated $487.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 679.0% from the prior year.

Net Income

$426.9M

YoY+154.6%

Biomarin Pharmaceutical Inc reported $426.9M in net income in fiscal year 2024. This represents an increase of 154.6% from the prior year.

EPS (Diluted)

$2.21

YoY+154.0%

Biomarin Pharmaceutical Inc earned $2.21 per diluted share (EPS) in fiscal year 2024. This represents an increase of 154.0% from the prior year.

Cash & Debt

$942.8M

YoY+24.9%

5Y CAGR+16.6%

10Y CAGR+0.7%

Biomarin Pharmaceutical Inc held $942.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

191M

YoY+1.1%

5Y CAGR+1.2%

10Y CAGR+1.8%

Biomarin Pharmaceutical Inc had 191M shares outstanding in fiscal year 2024. This represents an increase of 1.1% from the prior year.

Gross Margin

79.7%

YoY+1.7pp

5Y CAGR+0.8pp

10Y CAGR-4.0pp

Biomarin Pharmaceutical Inc's gross margin was 79.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 1.7 percentage points from the prior year.

Operating Margin

17.0%

YoY+9.3pp

5Y CAGR+22.9pp

10Y CAGR+29.4pp

Biomarin Pharmaceutical Inc's operating margin was 17.0% in fiscal year 2024, reflecting core business profitability. This is up 9.3 percentage points from the prior year.

Net Margin

15.0%

YoY+8.0pp

5Y CAGR+16.4pp

10Y CAGR+32.8pp

Biomarin Pharmaceutical Inc's net profit margin was 15.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 8.0 percentage points from the prior year.

Return on Equity

7.5%

YoY+4.1pp

Biomarin Pharmaceutical Inc's ROE was 7.5% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 4.1 percentage points from the prior year.

R&D Spending

$747.2M

YoY+0.1%

5Y CAGR+0.9%

10Y CAGR+4.9%

Biomarin Pharmaceutical Inc invested $747.2M in research and development in fiscal year 2024. This represents an increase of 0.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$85.4M

YoY-11.7%

5Y CAGR-10.0%

10Y CAGR-3.1%

Biomarin Pharmaceutical Inc invested $85.4M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 11.7% from the prior year.

BMRN Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$2.9B+18.0%	$2.4B+15.4%	$2.1B+13.5%	$1.8B-0.8%	$1.9B+9.2%	$1.7B
Cost of Revenue	$580.2M+9.1%	$532.1M+5.8%	$503.0M+6.9%	$470.5M-10.3%	$524.3M+45.8%	$359.5M
Gross Profit	$2.3B+20.5%	$1.9B+18.5%	$1.6B+15.8%	$1.4B+3.0%	$1.3B-0.6%	$1.3B
R&D Expenses	$747.2M+0.1%	$746.8M+15.0%	$649.6M+3.3%	$628.8M+0.1%	$628.1M-12.2%	$715.0M
SG&A Expenses	$1.0B+13.1%	$892.4M+8.4%	$823.2M+8.4%	$759.4M+2.9%	$737.7M+8.3%	$680.9M
Operating Income	$484.2M+160.6%	$185.8M+15.4%	$161.0M+295.5%	-$82.3M-89.6%	-$43.4M+56.8%	-$100.5M
Interest Expense	$12.7M-26.9%	$17.3M+8.5%	$16.0M+4.1%	$15.3M-47.7%	$29.3M+24.9%	$23.5M
Income Tax	$114.9M+449.3%	$20.9M+161.0%	$8.0M+171.1%	-$11.3M+98.8%	-$903.0M-1172.5%	-$71.0M
Net Income	$426.9M+154.6%	$167.6M+18.4%	$141.6M+320.9%	-$64.1M-107.5%	$854.0M+3681.1%	-$23.8M
EPS (Diluted)	$2.21+154.0%	$0.87+16.0%	$0.75+314.3%	$-0.35-107.8%	$4.50+3561.5%	$-0.13

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$776.1M-6.0%	$825.4M+10.8%	$745.1M-0.3%	$747.3M+5.0%	$712.0M+9.7%	$648.8M+0.4%	$646.2M+11.2%	$581.3M
Cost of Revenue	$140.1M-6.7%	$150.1M-1.0%	$151.6M+11.3%	$136.1M+4.4%	$130.5M+4.2%	$125.2M-9.2%	$137.9M+7.7%	$128.0M
Gross Profit	$636.0M-5.8%	$675.3M+13.8%	$593.6M-2.9%	$611.2M+5.1%	$581.6M+11.1%	$523.7M+3.0%	$508.3M+12.1%	$453.3M
R&D Expenses	$409.5M+153.8%	$161.3M+1.6%	$158.7M-8.5%	$173.5M-5.6%	$183.8M-10.3%	$205.0M-0.6%	$206.3M+7.8%	$191.3M
SG&A Expenses	$268.4M+15.6%	$232.3M+12.7%	$206.1M-22.7%	$266.6M+1.4%	$263.0M+16.4%	$225.9M-12.9%	$259.5M+20.3%	$215.8M
Operating Income	-$46.7M-116.9%	$276.9M+23.7%	$223.9M+38.7%	$161.4M+34.0%	$120.5M+36.2%	$88.5M+224.3%	$27.3M-10.6%	$30.5M
Interest Expense	$2.6M-3.7%	$2.7M-6.4%	$2.9M+11.1%	$2.6M-27.9%	$3.6M+0.8%	$3.5M-41.8%	$6.1M+61.4%	$3.8M
Income Tax	$4.4M-92.3%	$57.3M+9.4%	$52.4M+17.2%	$44.7M+79.1%	$25.0M+47.8%	$16.9M+1711.2%	-$1.0M-181.2%	$1.3M
Net Income	-$30.7M-112.8%	$240.5M+29.5%	$185.7M+48.6%	$124.9M+16.6%	$107.2M+20.9%	$88.7M+335.2%	$20.4M-49.5%	$40.4M
EPS (Diluted)	$-0.16-113.0%	$1.23+29.5%	$0.95+46.2%	$0.65+18.2%	$0.55+19.6%	$0.46+360.0%	$0.10-52.4%	$0.21

BMRN Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$7.0B+2.2%	$6.8B+7.3%	$6.4B+6.2%	$6.0B+2.7%	$5.8B+24.7%	$4.7B
Current Assets	$3.2B+9.3%	$3.0B+7.4%	$2.8B+21.0%	$2.3B-2.9%	$2.3B+20.6%	$1.9B
Cash & Equivalents	$942.8M+24.9%	$755.1M+4.2%	$724.5M+23.4%	$587.3M-9.5%	$649.2M+48.4%	$437.4M
Inventory	$1.2B+11.3%	$1.1B+23.8%	$894.1M+15.1%	$776.7M+11.2%	$698.5M+2.7%	$680.3M
Accounts Receivable	$660.5M+4.2%	$633.7M+37.4%	$461.3M+23.5%	$373.4M-16.7%	$448.4M+18.8%	$377.4M
Goodwill	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M-0.4%	$197.0M
Total Liabilities	$1.3B-29.6%	$1.9B+6.7%	$1.8B+1.9%	$1.7B-0.2%	$1.7B+11.1%	$1.6B
Current Liabilities	$607.0M-48.4%	$1.2B+99.9%	$588.9M+7.8%	$546.5M+11.0%	$492.5M-47.2%	$932.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.7B+14.3%	$5.0B+7.6%	$4.6B+7.9%	$4.3B+4.0%	$4.1B+31.3%	$3.1B
Retained Earnings	-$194.7M+68.7%	-$621.6M+21.2%	-$789.2M+15.2%	-$930.8M-8.0%	-$861.6M+49.9%	-$1.7B

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$7.6B+2.1%	$7.5B+4.3%	$7.1B+2.3%	$7.0B-1.1%	$7.1B+2.8%	$6.9B+0.5%	$6.8B+1.2%	$6.8B
Current Assets	$3.9B+1.3%	$3.8B+9.7%	$3.5B+7.3%	$3.2B-0.8%	$3.3B+9.2%	$3.0B+1.0%	$3.0B0.0%	$3.0B
Cash & Equivalents	$1.3B+3.0%	$1.2B+15.7%	$1.0B+11.2%	$942.8M-3.0%	$972.1M+30.1%	$747.0M-1.1%	$755.1M-3.9%	$785.4M
Inventory	$1.4B+3.1%	$1.3B+5.1%	$1.3B+3.4%	$1.2B+4.1%	$1.2B+4.0%	$1.1B+2.8%	$1.1B+7.3%	$1.0B
Accounts Receivable	$790.3M-7.7%	$855.9M+15.8%	$739.2M+11.9%	$660.5M-4.4%	$691.2M+8.5%	$637.2M+0.5%	$633.7M+10.7%	$572.5M
Goodwill	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M
Total Liabilities	$1.6B+9.0%	$1.4B+5.6%	$1.4B+1.7%	$1.3B-25.3%	$1.8B-1.0%	$1.8B-4.8%	$1.9B+1.5%	$1.9B
Current Liabilities	$798.4M+16.7%	$684.2M+8.9%	$628.2M+3.5%	$607.0M-43.1%	$1.1B-1.9%	$1.1B-7.6%	$1.2B+1.2%	$1.2B
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.1B+0.5%	$6.0B+4.0%	$5.8B+2.4%	$5.7B+7.0%	$5.3B+4.2%	$5.1B+2.5%	$5.0B+1.1%	$4.9B
Retained Earnings	$200.8M-13.3%	$231.5M+2669.9%	-$9.0M+95.4%	-$194.7M+54.3%	-$425.7M+20.1%	-$532.9M+14.3%	-$621.6M+3.2%	-$641.9M

BMRN Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$572.8M+259.7%	$159.3M-9.5%	$175.9M-42.2%	$304.5M+256.7%	$85.4M+76.9%	$48.3M
Capital Expenditures	$85.4M-11.7%	$96.7M-20.1%	$121.0M+26.6%	$95.6M-16.4%	$114.3M-21.2%	$145.0M
Free Cash Flow	$487.4M+679.0%	$62.6M+13.9%	$54.9M-73.7%	$209.0M+821.9%	-$28.9M+70.1%	-$96.8M
Investing Cash Flow	$136.5M+222.7%	-$111.2M-455.4%	-$20.0M+94.5%	-$366.3M-583.2%	-$53.6M-72.8%	-$31.0M
Financing Cash Flow	-$526.4M-2711.2%	-$18.7M-0.4%	-$18.6M-38754.2%	-$48K-100.0%	$181.1M+342.5%	-$74.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$0	$0-100.0%	$50.0M	$0

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	$368.7M+99.0%	$185.3M+6.2%	$174.4M-6.1%	$185.6M+56.3%	$118.8M+152.8%	$47.0M+70.9%	$27.5M-79.7%	$135.6M
Capital Expenditures	$28.4M+66.3%	$17.1M+2.0%	$16.8M-14.1%	$19.5M-8.4%	$21.3M-18.3%	$26.1M-9.7%	$28.9M+33.0%	$21.7M
Free Cash Flow	$340.2M+102.3%	$168.2M+6.7%	$157.6M-5.1%	$166.1M+70.5%	$97.4M+366.9%	$20.9M+1555.2%	-$1.4M-101.3%	$113.9M
Investing Cash Flow	-$331.0M-2528.4%	-$12.6M+55.4%	-$28.2M-137.0%	$76.4M-15.6%	$90.5M+735.6%	-$14.2M+78.1%	-$65.0M-41.8%	-$45.8M
Financing Cash Flow	-$2.2M+52.9%	-$4.6M+88.1%	-$38.8M-1456.4%	$2.9M-77.3%	$12.6M+129.5%	-$42.8M-494.8%	$10.8M+1475.6%	-$788K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BMRN Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	79.7%+1.7pp	78.0%+2.0pp	76.0%+1.5pp	74.5%+2.7pp	71.8%-7.1pp	78.9%
Operating Margin	17.0%+9.3pp	7.7%0.0pp	7.7%+12.1pp	-4.5%-2.1pp	-2.3%+3.6pp	-5.9%
Net Margin	15.0%+8.0pp	6.9%+0.2pp	6.8%+10.2pp	-3.5%-49.4pp	45.9%+47.3pp	-1.4%
Return on Equity	7.5%+4.1pp	3.4%+0.3pp	3.1%	N/A	20.8%	N/A
Return on Assets	6.1%+3.7pp	2.5%+0.2pp	2.2%+3.3pp	-1.1%-15.7pp	14.6%+15.1pp	-0.5%
Current Ratio	5.33+2.8	2.51-2.2	4.67+0.5	4.16-0.6	4.76+2.7	2.08
Debt-to-Equity	0.24-0.1	0.380.0	0.38-0.0	0.41-0.0	0.42-0.1	0.50
FCF Margin	17.1%+14.5pp	2.6%-0.0pp	2.6%-8.7pp	11.3%+12.9pp	-1.6%+4.1pp	-5.7%

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	82.0%+0.1pp	81.8%+2.2pp	79.7%-2.1pp	81.8%+0.1pp	81.7%+1.0pp	80.7%+2.1pp	78.7%+0.7pp	78.0%
Operating Margin	-6.0%-39.6pp	33.6%+3.5pp	30.0%+8.4pp	21.6%+4.7pp	16.9%+3.3pp	13.6%+9.4pp	4.2%-1.0pp	5.3%
Net Margin	-4.0%-33.1pp	29.1%+4.2pp	24.9%+8.2pp	16.7%+1.7pp	15.0%+1.4pp	13.7%+10.5pp	3.1%-3.8pp	7.0%
Return on Equity	N/A	4.0%+0.8pp	3.2%+1.0pp	2.2%+0.2pp	2.0%+0.3pp	1.8%+1.3pp	0.4%-0.4pp	0.8%
Return on Assets	-0.4%-3.6pp	3.2%+0.6pp	2.6%+0.8pp	1.8%+0.3pp	1.5%+0.2pp	1.3%+1.0pp	0.3%-0.3pp	0.6%
Current Ratio	4.83-0.7	5.56+0.0	5.52+0.2	5.33+2.3	3.05+0.3	2.74+0.2	2.51-0.0	2.54
Debt-to-Equity	0.26+0.0	0.240.0	0.230.0	0.24-0.1	0.34-0.0	0.35-0.0	0.380.0	0.38
FCF Margin	43.8%+23.5pp	20.4%-0.8pp	21.1%-1.1pp	22.2%+8.5pp	13.7%+10.5pp	3.2%+3.4pp	-0.2%-19.8pp	19.6%

Similar Companies

Ionis Pharmaceuticals IONS

$13.1B

Bridgebio Pharma BBIO

$14.4B

Exelixis Inc EXEL

$11.4B

Ascendis Pharma ASND

$13.3B

Summit Therapeutics Inc SMMT

$11.1B

Frequently Asked Questions

What is Biomarin Pharmaceutical Inc's annual revenue?

Biomarin Pharmaceutical Inc (BMRN) reported $2.9B in total revenue for fiscal year 2024. This represents a 18.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Biomarin Pharmaceutical Inc's revenue growing?

Biomarin Pharmaceutical Inc (BMRN) revenue grew by 18% year-over-year, from $2.4B to $2.9B in fiscal year 2024.

Is Biomarin Pharmaceutical Inc profitable?

Yes, Biomarin Pharmaceutical Inc (BMRN) reported a net income of $426.9M in fiscal year 2024, with a net profit margin of 15.0%.

What is Biomarin Pharmaceutical Inc's earnings per share (EPS)?

Biomarin Pharmaceutical Inc (BMRN) reported diluted earnings per share of $2.21 for fiscal year 2024. This represents a 154.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Biomarin Pharmaceutical Inc's EBITDA?

Biomarin Pharmaceutical Inc (BMRN) had EBITDA of $580.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Biomarin Pharmaceutical Inc's gross margin?

Biomarin Pharmaceutical Inc (BMRN) had a gross margin of 79.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Biomarin Pharmaceutical Inc's operating margin?

Biomarin Pharmaceutical Inc (BMRN) had an operating margin of 17.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Biomarin Pharmaceutical Inc's net profit margin?

Biomarin Pharmaceutical Inc (BMRN) had a net profit margin of 15.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Biomarin Pharmaceutical Inc's return on equity (ROE)?

Biomarin Pharmaceutical Inc (BMRN) has a return on equity of 7.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Biomarin Pharmaceutical Inc's free cash flow?

Biomarin Pharmaceutical Inc (BMRN) generated $487.4M in free cash flow during fiscal year 2024. This represents a 679.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Biomarin Pharmaceutical Inc's operating cash flow?

Biomarin Pharmaceutical Inc (BMRN) generated $572.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Biomarin Pharmaceutical Inc's total assets?

Biomarin Pharmaceutical Inc (BMRN) had $7.0B in total assets as of fiscal year 2024, including both current and long-term assets.

What are Biomarin Pharmaceutical Inc's capital expenditures?

Biomarin Pharmaceutical Inc (BMRN) invested $85.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Biomarin Pharmaceutical Inc spend on research and development?

Biomarin Pharmaceutical Inc (BMRN) invested $747.2M in research and development during fiscal year 2024.

How many shares does Biomarin Pharmaceutical Inc have outstanding?

Biomarin Pharmaceutical Inc (BMRN) had 191M shares outstanding as of fiscal year 2024.

What is Biomarin Pharmaceutical Inc's current ratio?

Biomarin Pharmaceutical Inc (BMRN) had a current ratio of 5.33 as of fiscal year 2024, which is generally considered healthy.

What is Biomarin Pharmaceutical Inc's debt-to-equity ratio?

Biomarin Pharmaceutical Inc (BMRN) had a debt-to-equity ratio of 0.24 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Biomarin Pharmaceutical Inc's return on assets (ROA)?

Biomarin Pharmaceutical Inc (BMRN) had a return on assets of 6.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Biomarin Pharmaceutical Inc's Altman Z-Score?

Biomarin Pharmaceutical Inc (BMRN) has an Altman Z-Score of 6.23, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Biomarin Pharmaceutical Inc's Piotroski F-Score?

Biomarin Pharmaceutical Inc (BMRN) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Biomarin Pharmaceutical Inc's earnings high quality?

Biomarin Pharmaceutical Inc (BMRN) has an earnings quality ratio of 1.34x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Biomarin Pharmaceutical Inc cover its interest payments?

Biomarin Pharmaceutical Inc (BMRN) has an interest coverage ratio of 38.2x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Biomarin Pharmaceutical Inc?

Biomarin Pharmaceutical Inc (BMRN) scores 80 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.